MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - MYLAN (US)
VENUS REMEDIES vs MYLAN (US) - Comparison Results
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 VENUS REMEDIES  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
MYLAN Dec-18 |
VENUS REMEDIES/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 3,547 | - | |
| Low | Rs | 61 | 1,952 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 1,632.0 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | 44.3 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | 349.9 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 293.3 | 1,765.5 | - | |
| Shares outstanding (eoy) | m | 12.34 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 1.7 | 18.4% | |
| Avg P/E ratio | x | -3.8 | 62.0 | -6.1% | |
| P/CF ratio (eoy) | x | 36.7 | 7.9 | 467.6% | |
| Price / Book Value ratio | x | 0.3 | 1.6 | 20.5% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,154 | 1,414,576 | 0.1% | |
| No. of employees | `000 | 0.9 | 35.0 | 2.6% | |
| Total wages/salary | Rs m | 393 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,026.1 | 23,990.1 | 16.8% | |
| Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -331.8 | 651.4 | -50.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 839,653 | 0.4% | |
| Other income | Rs m | 23 | 0 | - | |
| Total revenues | Rs m | 3,747 | 839,653 | 0.4% | |
| Gross profit | Rs m | 395 | 217,271 | 0.2% | |
| Depreciation | Rs m | 338 | 157,216 | 0.2% | |
| Interest | Rs m | 354 | 40,384 | 0.9% | |
| Profit before tax | Rs m | -275 | 19,671 | -1.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 32 | -3,129 | -1.0% | |
| Profit after tax | Rs m | -307 | 22,800 | -1.3% | |
| Gross profit margin | % | 10.6 | 25.9 | 41.0% | |
| Effective tax rate | % | -11.5 | -15.9 | 72.1% | |
| Net profit margin | % | -8.2 | 2.7 | -303.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 468,862 | 0.6% | |
| Current liabilities | Rs m | 2,305 | 341,852 | 0.7% | |
| Net working cap to sales | % | 8.9 | 15.1 | 59.1% | |
| Current ratio | x | 1.1 | 1.4 | 83.4% | |
| Inventory Days | Days | 135 | 84 | 162.1% | |
| Debtors Days | Days | 46 | 93 | 49.6% | |
| Net fixed assets | Rs m | 4,871 | 162,879 | 3.0% | |
| Share capital | Rs m | 123 | 447 | 27.6% | |
| Net worth | Rs m | 3,619 | 908,351 | 0.4% | |
| Long term debt | Rs m | 1,374 | 980,403 | 0.1% | |
| Total assets | Rs m | 7,509 | 2,436,552 | 0.3% | |
| Interest coverage | x | 0.2 | 1.5 | 15.0% | |
| Debt to equity ratio | x | 0.4 | 1.1 | 35.2% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 143.9% | |
| Return on assets | % | 0.6 | 2.6 | 24.3% | |
| Return on equity | % | -8.5 | 2.5 | -337.8% | |
| Return on capital | % | 1.6 | 3.2 | 49.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 174,480 | 0.3% | |
| From Investments | Rs m | -123 | -90,187 | 0.1% | |
| From Financial Activity | Rs m | -387 | -81,283 | 0.5% | |
| Net Cashflow | Rs m | 4 | 1,445 | 0.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.51 Rs / USD
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: ALEMBIC PHARMA TTK HEALTHCARE PFIZER AJANTA PHARMA DISHMAN PHARMA
Today's Market
Sensex Dives Over 1,100 Points, Dow Futures Down by 119 Points(12:30 pm)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
